Harnessing protease activity to improve cancer care
Proteolysis plays critical roles in normal and pathologic physiology; these enzymes are intricately involved in cancer progression and spread. Our understanding of protease function has advanced from nonspecific degrading enzymes to a modern appreciation of their diverse roles in posttranslational m...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Annual Reviews
2020
|
| Online Access: | https://hdl.handle.net/1721.1/124760 |
| _version_ | 1826215300332257280 |
|---|---|
| author | Dudani, Jaideep S. Warren, Andrew D. Bhatia, Sangeeta N. |
| author2 | Harvard University--MIT Division of Health Sciences and Technology |
| author_facet | Harvard University--MIT Division of Health Sciences and Technology Dudani, Jaideep S. Warren, Andrew D. Bhatia, Sangeeta N. |
| author_sort | Dudani, Jaideep S. |
| collection | MIT |
| description | Proteolysis plays critical roles in normal and pathologic physiology; these enzymes are intricately involved in cancer progression and spread. Our understanding of protease function has advanced from nonspecific degrading enzymes to a modern appreciation of their diverse roles in posttranslational modification and signaling in a complex microenvironment. This new understanding has led to next-generation diagnostics and therapeutics that exploit protease activity in cancer. For diagnostics, protease activity may be measured as a biomarker of cancer, with wide-ranging utility from early detection to monitoring therapeutic response. Therapeutically, while broad inhibition of protease activity proved disappointing, new approaches that more specifically modulate proteases in concert with secondary targets might enable potent combination therapies. In addition, clinical evaluation is underway for tools that leverage protease activity to activate therapeutics, ranging from imaging agents that monitor surgical margins to immunotherapies with improved specificity. Technologies that interact with, measure, or modulate proteases are poised to improve cancer management on diagnostic and therapeutic fronts to realize the promise of precision medicine. ©2018 Keywords: protease activity; degradomics; activity-based biomarkers; responsive nanomaterials; protease-targeted therapeutics; protease-triggered therapeutics |
| first_indexed | 2024-09-23T16:22:34Z |
| format | Article |
| id | mit-1721.1/124760 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T16:22:34Z |
| publishDate | 2020 |
| publisher | Annual Reviews |
| record_format | dspace |
| spelling | mit-1721.1/1247602022-09-29T19:42:46Z Harnessing protease activity to improve cancer care Dudani, Jaideep S. Warren, Andrew D. Bhatia, Sangeeta N. Harvard University--MIT Division of Health Sciences and Technology Koch Institute for Integrative Cancer Research at MIT Proteolysis plays critical roles in normal and pathologic physiology; these enzymes are intricately involved in cancer progression and spread. Our understanding of protease function has advanced from nonspecific degrading enzymes to a modern appreciation of their diverse roles in posttranslational modification and signaling in a complex microenvironment. This new understanding has led to next-generation diagnostics and therapeutics that exploit protease activity in cancer. For diagnostics, protease activity may be measured as a biomarker of cancer, with wide-ranging utility from early detection to monitoring therapeutic response. Therapeutically, while broad inhibition of protease activity proved disappointing, new approaches that more specifically modulate proteases in concert with secondary targets might enable potent combination therapies. In addition, clinical evaluation is underway for tools that leverage protease activity to activate therapeutics, ranging from imaging agents that monitor surgical margins to immunotherapies with improved specificity. Technologies that interact with, measure, or modulate proteases are poised to improve cancer management on diagnostic and therapeutic fronts to realize the promise of precision medicine. ©2018 Keywords: protease activity; degradomics; activity-based biomarkers; responsive nanomaterials; protease-targeted therapeutics; protease-triggered therapeutics 2020-04-21T16:11:28Z 2020-04-21T16:11:28Z 2018-03 2017-12 2019-05-09T17:25:46Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/124760 Dudani, Jaideep S., Andrew D. Warren, and Sangeeta N. Bhatia, "Harnessing protease activity to improve cancer care." Annual review of cancer biology 2 (2018): p. 353-76 doi 10.1146/ANNUREV-CANCERBIO-030617-050549 ©2018 Author(s) en 10.1146/ANNUREV-CANCERBIO-030617-050549 Annual review of cancer biology Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Annual Reviews Other repository |
| spellingShingle | Dudani, Jaideep S. Warren, Andrew D. Bhatia, Sangeeta N. Harnessing protease activity to improve cancer care |
| title | Harnessing protease activity to improve cancer care |
| title_full | Harnessing protease activity to improve cancer care |
| title_fullStr | Harnessing protease activity to improve cancer care |
| title_full_unstemmed | Harnessing protease activity to improve cancer care |
| title_short | Harnessing protease activity to improve cancer care |
| title_sort | harnessing protease activity to improve cancer care |
| url | https://hdl.handle.net/1721.1/124760 |
| work_keys_str_mv | AT dudanijaideeps harnessingproteaseactivitytoimprovecancercare AT warrenandrewd harnessingproteaseactivitytoimprovecancercare AT bhatiasangeetan harnessingproteaseactivitytoimprovecancercare |